- When to consider referring for low-vision rehabilitation
- The role of sex hormones and aging in dry eye disease
- 3 reasons to read AOA’s newest clinical practice guideline
- Identifying reading difficulties in children
- Mobilizing against myopia
- New AOA clinical guideline puts focus on elevating care of glaucoma patients
- Tips for reinforcing optometry’s role in the broader health care system
- Vision loss makes list of 14 risk factors for dementia
- The ‘gatekeepers of primary eye care’
- Myopia report calls for disease classification, new federal policies
- High-tech solutions for low vision
- Optometrists play an integral role in assessing and treating patients with traumatic brain injuries.
- Primary care of the stroke patient
- Research on eye aberrations not abstract to award-winning scientists
- AOA, CooperVision mobilize to ‘disrupt the status quo,’ advance new standard of care for children with myopia
- What do the experts say on genetic testing for IRDs?
- Pediatric keratoconus prevalence higher than believed, may change care approach
- Making blurry vision clear
- Unblurring the lines
- Appreciating optometry’s value to patients with diabetes and their primary care physicians
- 9 benefits of introducing laser procedures into your practice
- 5 considerations if you’re thinking about adding laser procedures to your practice
- Optometrist-performed YAG capsulotomies shown effective, safe and beneficial for patients
- For 128 million U.S. presbyopes, doctors of optometry can provide treatment options
- What’s up, doc? Can a dietary supplement reverse patient cataracts?
- Legal blindness in America
- AOA webinar addresses concerns about myopia management
- AOA serving patients through research in optometry
- Marijuana sensibilities changing fast: Are you ready for patients’ questions?
- Buzz builds for AOA virtual ePosters event
- New AOA adult eye guideline
- New technology for the advanced AMD patient
- Interprofessional communication for diabetic eye care
- Contact lens experts weigh in on gaps in consumer knowledge
- Align your team on binocular vision disorders
- How to better manage dry eye disease
- eyes the brain and learning
- Can vision intervention slow onset of dementia
- New independent task force recommendation on glaucoma screening underwhelms
- Gene therapy vision rehabilitation for IRDs
- 2022 contact lens controversies
- The latest research from AOA members
- Caring for patients with special needs
- New discoveries aid understanding of the visual system
- Don’t let the pressure get to you or your patients
- How technology has changed recommendations for visually impaired children
- 12 ways to provide better care for patients with prediabetes and diabetes
- Alzheimers and eyes
- Level up your diabetes care with specialists, services collaboration
- Behind the lens
- Contact lens developments regarding keratoconus
- Managing the care of patients with contact lens-related dry eye
- Lens-based strategies to address reading issues due to mild, disease-related vision loss
- Study shines light on optogenetics in retinitis pigmentosa
- surgical procedures courses
- Genetic Testing and Gene Therapy
- low vision in your practice
- Low percentage of patients with diabetes adhere to key self-care practices
- EBO to produce new glaucoma clinical practice guideline
- details of visual functions immediately following marijuana use
- Understanding Photophobia in mTBI
- New myopia management guidance released
- The challenges of maintaining a healthy tear film
- Integrating models of diabetic eye care
- Dry Eye and Productivity
- Contact lens innovation delivers opportunity
- How face masks affect the eyes
- Marijuana dispensaries still blow smoke over glaucoma effects
- Conjunctival Lymphangiectasia and Fabry
- Techniques to enhance contrast
- Americans remain at high risk for vision loss
- Stimulating eye and vision research
- Allergic conjunctivitis in a COVID-19 world
- Atropine in myopia control
- sleep patients ocular health
- CDC US coronavirus spread expected
- Demystifying dizziness
- Optometry and Glaucoma patients
- 5 reasons why doctors should use AOA diabetes guideline
- Growing epidemic of adolescents and young adults with prediabetes
- Improving scanning efficiency of individuals with homonymous hemianopia
- second edition of diabetes clinical practice guideline
- Pupil patterns in youth a phenomenon
- Study high school sports concussions underscores optometry role in care
- Prototype imager of tear film sublayers opens eyes on dry eye
- Retinal measurements hold clues to Alzheimers disease
- reversing prediabetes to normoglycemia can lessen microvascular complication risk
- Detecting the signs of autism at earlier age using visual cues
- Eye disorder CRISPR technology
- Addressing elderly vision impairment
- The AMD aspirin balancing act
- Study looks at what patients understand about their glaucoma diagnoses
- Vision Rehabilitation Clinical Pearls Lens Rx Prescribing for the Patient with Traumatic Brain Injury
- Real partners in diabetes care
- Amblyopia More than meets the eye
- New mild TBI guideline for children provides opportunity for doctors of optometry
- Reading corneal signs
- Eyes on Alzheimers disease
- Study looks at potential of suppressing ocular cancer in children
- Doctors of optometry are members of post-concussion team
- Glaucoma & Exercise
- The ABCs of MGD
- When T-cells go bad
- Study opens eyes to Alzheimers disease risk
- Understanding MGD
- Sjogren’s dry eye disease and depression
- Are patches the answer to amblyopia
- Oranges may allay AMD risk Pulp fact or fiction
- myopiatech
- Cognitive Decline
- Myopia Genes Discovered
- Link between diabetes and MGD
- alzheimers clues could be found using eye scan
- Genetic markers may help predict elevated IOP
- Ebola vector-borne diseases rear ugly heads again
- Blue lights link to prostate and breast cancers
- Can dyed contact lenses help color perception in CVD patients
- Omega 3 and Dry Eyes
- Glaucoma-Cannabinoid NP Drop
- Genetic Testing for AMD
- Premature Babies Low Birthweight Eyes
- ASD & Accommodative Function
- Stem Cells and Wet AMD
- Sjogren Awareness
- Brain Injury Awareness
- Sleep apneas interplay with corneal hysteresis
- New blood pressure guideline
- Low vision patient future
- Retinoblastoma-detecting ocular cancer in children
- Winter Dry Eye
- Low Vision and Blindness to Double
- New guidelines detecting retinoblastoma in children
- Glaucoma protein biomarker
- Risk for normal-tension glaucoma rises
- Peripheral reaction time faster in deaf adults
- New therapeutic target could reduce diabetic retinopathy
- diabetes on the rise among the young
- Trabeculoplasty Commentary
- Seniors near vision loss dementia risk linked
- Can frequent anti VEGF injections increase glaucoma surgery risk
- Study stresses stress test in treating patients with AMD
- Contact lens helps predict speed of glaucoma progression
- Unique retinal cell dysfunction triggers myopia
- Preeclampsia years later still takes toll
- How tilted optic discs may affect myopic eyes
- New eye test is early detector of diabetes
- Anti VEGF injections may not work for allglaucoma sooner
- New technique could diagnose glaucoma sooner
- Myopia incidence piques control efforts initiatives
- Study links visual impairment to physical and cognitive function declines
- Benefits unfamiliarity proves barrier to diabetes care
- Eyes on Alzheimers
- Association found between TBI and neurodegenerative conditions
- Spotting the link between vision problems and ADHD
- Treating the digital eye
- Statins show continued potential as treatment for dry AMD
- How doctors of optometry can diagnose a rare disorder
- Could eye drops be an alternative treatment to cataract surgery
- Researchers zero in on potential dry AMD treatment
- Ranibizumab proves effective to treat proliferative diabetic retinopathy
- Study shows some drivers with glaucoma naturally adapt
- Doctors of optometry a crucial component in cataract care
- Be part of the national dialogue about diabetes
- Under pressure addressing hypertension
- Gene therapy successful in treating rare retinal disorder
- The lowdown on treating low vision patients
- New study calls attention to importance of carotenoids
- 5 things doctors of optometry should know about concussions
- Can a supplement fight diabetic retinopathy
- Outdoor activity may reduce risk for myopia in children
- 3 reasons comprehensive exams matter for diabetes
- Diabetes and Prediabetes
- Vitamin C may slow progress of cataracts
- Multifocal contact lens effective at treating myopia in kids
- New tool educates and motivates patients with diabetes related eye disease
- Myopia Its in your genes too
- Out of the box thinking leads to potential glaucoma treatment
- Doctors of optometry have big role in catching giant cell arteritis before blindness
- Cataract surgery lessens death risk
- Novel glaucoma therapy One ring to help them all
- Common glaucoma drugs may affect IOP measurements
- Gene mutation uncovers potential treatment for rare form of pediatric glaucoma
- How astigmatism affects reading fluency
- FDA approves first corneal cross linking system for treatment
- Cataracts and UV exposure in driver-side windows
- Virtual model aids diabetic retinopathy progression understanding
- doctors of optometry AMD assessments comparable to ophthalmologistsoutcomes
- Parkinsons detectable through eye exam
- Are sleep apnea and asthma linked to keratoconus
- Not a dry eye
- Eye on head injuries
- Risk for macular degeneration linked to low levels of vitamin D
- Tears now fears Zika persists in eyes
- Myopia Controlling the heretofore uncontrollable
- advancing keratoconus care
- visual dysfunction after brain injury
- Study detects early biomarkers for risk of developing diabetic retinopathy
- Prevalence of Undiagnosed AMD
- Daily use of steroid drops increases risk for ocular hypertension
- Zikababy
- New study dry eye disease
- Encyclopedia of dry eye disease released
- Clinical Pearls for Seasonal Allergies
- Doctors of optometry less likely to prescribe seldom needed antibiotics for conjunctivitis
- T cells hold promise of treatment for preemies born with eye condition
- Youth Concussions
- New imaging techniques detect earlystage Alzheimer’s disease
Solving the myopia mystery
August 31, 2023
Significant clinical studies on atropine for myopia control show conflicting results for doctors of optometry seeking a solution to myopia progression. More research is needed on atropine dosage and why results were different among children living in the U.S. and Asia.
There are more randomized clinical studies on atropine eye drops for myopia control, but this time did it work in U.S. children?
On July 13, the National Institutes of Health (NIH) reported on the results of a two-year NIH-funded trial, which found that low-dose atropine eye drops (concentration 0.01%) worked no better than a placebo in slowing the progression of myopia in school-age children in the U.S., according to the study published in JAMA Ophthalmology.
As the NIH noted, the findings in the July trial “contradict” historical results in East Asia where nightly use of low-dose atropine eye drops slowed myopia progression. The contradictory results raised more questions than answers about atropine as a treatment for myopia. In February, news broke in JAMA online of another randomized trial from The Chinese University of Hong Kong that suggested nightly doses of atropine may have the potential to delay or prevent the onset of myopia in children. “The difference between 0.05% atropine and placebo was statistically significant,” but 0.01% atropine was not, wrote that study’s authors.
And on June 1, JAMA Ophthalmology published results of another study suggesting low-dose atropine (0.01%) was effective and safe and “may provide a treatment option for childhood myopia progression.” Karla Zadnik, O.D., Ph.D., dean of The Ohio State University College of Optometry, is the lead author. The treatment effect of atropine 0.01% was slightly less than 0.25 D over three years. There was no significant difference in refractive error with atropine 0.02% compared with placebo.
Although effective, stronger concentrations of atropine (0.5% to 1.0%) have more side effects, including light sensitivity and blurry near vision, the NIH says.
“The overall mixed results on low-dose atropine show us we need more research,” reacted Michael Chiang, M.D., director of the National Eye Institute, part of the NIH. “Would a different dose be more effective in a U.S. population? Would combining atropine with other strategies have a synergistic effect? Could we develop other approaches to treatment or prevention based on a better understanding of what causes myopia progression?”
The NIH article expressed some urgency about getting the dosage correct given that by 2050 an estimated 44 million people in the U.S. are expected to have myopia.
“The new study means we need to study atropine more!” says study co-author Katherine Weise, O.D., MBA, University of Alabama at Birmingham School of Optometry. “More optometrists need to be thinking about what we can do to solve the myopia mystery. It may be higher concentrations of atropine. It may be special glasses or contact lenses. It may be environmental interventions. The more people we can get thinking about myopia, the better.
“It will take a real convergence of eye research to solve the environmental, genetic, and structural mystery of myopia,” Dr. Weise adds. “Any time we can provide our patients with treatment outcomes from gold standard research, we are helping in so many ways. Parents can be armed with knowledge to make the best decisions for their children.”
Latest study results on children’s myopia
In the study released in July, 187 children ages 5 to 12 years were given either nightly atropine or placebo. The eye drops did not slow myopia progression or axial elongation, write that study’s authors. The trial’s children were from diverse races/ethnicities including white, Black, East Asian, Hispanic or Latino, multiracial and West/South Asian.
“These results do not support use of atropine, 0.01%, eye drops to slow myopia progression or axial elongation in U.S. children,” say the study authors, members of the Pediatric Eye Disease Investigator Group, a collaboration of optometrists and ophthalmologists that conducted the study. Among their findings:
- No significant differences between the groups (atropine vs. placebo) in degree of myopia compared with baseline.
- No significant differences in axial length within the two groups when compared with baseline measurements.
“The latest NIH study from Repka et al. did not find that 0.01% atropine slows myopia progression or eye growth,” says David Berntsen, O.D., Ph.D. Dr. Berntsen is the clinical sciences department chair at the University of Houston College of Optometry. He and Jeffrey Walline, O.D., Ph.D., associate dean for research at The Ohio State University, co-authored an editorial, “Delaying the Onset of Nearsightedness,” that accompanied the study (in China) released in February.
Continues Dr. Berntsen: “This finding adds to the growing number of studies finding variable results with 0.01% atropine. Results in primarily Asian children in Asia using 0.01% atropine show a little more consistency (though not always) in slowing myopia progression and eye growth than in primarily Caucasian samples. Speculation about why this may be true includes improved compliance in Asian children, longer drug activity in children with dark irides, and faster myopia progression among children in Asia.”
Weise notes that in the NIH study there was a 94% retention rate at 2.5 years and more than 90% of the children documented “excellent” (76% to 100% of the time compliance).
Optometry has a part to play in myopia control
As they did earlier, Drs. Berntsen and Walline continue to support more research to solve the contradiction, so effective and safe treatment options can be provided to patients.
“Research continues to monitor myopia progression and eye growth with a variety of low concentrations, generally ranging from 0.01% to 0.05% atropine, and should include a direct comparison of children of various races to determine whether one group is more likely to benefit from myopia control than another,” Dr. Walline says.
Yet myopia has proven a tough nut to crack.
“We aren't exactly sure how myopia affects the growth of the eye,” Dr. Weise says. “It was initially thought to be related to accommodation. We don't think that's true anymore. Then, we learned that atropine made it all the way back to the retina, where it might have an effect. We think maybe it also affects the choroid. So, if we don't really know how it works, it's hard to determine treatment regimens that work. There is also variability in how the atropine drops are manufactured. There are also more side effects and more rebound effects in concentrations that are more effective. Then, adding cost for the families and even getting a child to use a drop nightly for a treatment that provides no immediate visual benefit (such as special contact lenses or special glasses, e.g.), atropine becomes a spider web of question marks.
“Optometrists should dig into the myopia literature,” she says. “Optometry has been studying myopia for decades. But now, we are welcoming more pediatricians, researchers and eye care providers to the conversation. The more questions we get asked, the more answers we'll seek. With the right collaborations and care, optometry can play a major role in our myopia understandings.”
Drs. Walline and Berntsen note that no one treatment may work for all patients. Doctors of optometry might consider low-dose atropine in combination with other treatment options. Perhaps a secondary treatment?
Atropine can be a better fit than contact lenses for patients with high astigmatism or children not ready for contacts, says Dr. Walline, adding, “We also do not currently have access to promising novel spectacle designs for myopia control in the U.S.
“In addition to considering atropine as a primary myopia control treatment, optometrists should consider low-concentration atropine as a secondary treatment to be used when the parent or doctor don’t feel that an optical treatment provides enough myopia control,” he says. “Most studies indicate better myopia control for children who are provided both an optical treatment (glasses or contact lenses) and atropine when compared to optical treatment alone. Therefore, atropine may be considered as an adjunctive treatment when myopia seems to progress too quickly when already on an optical myopia control treatment regimen.”
Like Dr. Weise, they also sound a cautionary note about compounding or the manufacturing of atropine.
Recent studies have raised concerns about the lack of standardization of compounded low concentrations of atropine for myopia control. One study looked at compounding pharmacies and concluded that “an inconsistent and wide variety of formulation and labeling practices exist for compounding 0.01% atropine prescribed to slow pediatric myopia progression.”
“At this time, low-concentration atropine must be formulated by a compounding pharmacy,” Dr. Berntsen says. “Unfortunately, compounding pharmacies don’t use a standard protocol to formulate low-concentration atropine, which may affect the consistency, stability, effectivity and comfort of the drops. A company that receives Food and Drug Administration approval for myopia control with low-concentration atropine will likely provide us with a consistent and stable formulation that we can trust to prescribe to our patients.”
Children’s vision resources from the AOA
View AOA resources for children’s vision.
Read the Clinical Report: Myopia Management produced by the AOA’s Evidence-based Optometry Committee.